HomeScientific Advisory Board

Scientific Advisory Board

https://stuarttherapeutics.com/wp-content/uploads/New-Advisory-Board-New-Ronald-LR2.png

Ronald T. Raines, PhD.

Go to full bio >

Jay Pepose

Jay Pepose , MD.

Go to full bio >
https://stuarttherapeutics.com/wp-content/uploads/New-Advisory-Board-Ed-LR5.png

Ed Holland, MD.

Go to full bio >
https://stuarttherapeutics.com/wp-content/uploads/Vance-Headshop-LR3.png

Vance Thompson, MD.

Go to full bio >
Felipe Headshot

Felipe Medeiros

Go to full bio >

https://stuarttherapeutics.com/wp-content/uploads/Peter-LR2.png

Peter Kaiser, MD.

Go to full bio >
POLYCOL

Stuart Therapeutics has recently completed its Phase 2 clinical trial for its first drug candidate, ST-100 for Dry Eye Disease. The company has also completed extensive in vitro and in vivo research to profile the multiple amino acid sequence variants of the PolyCol platform, including their impact on accelerating tissue healing and reduction of inflammation in other important ophthalmic indications.